EAA241
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
- NCT07085728 ↗
- Recruiting
- Eastern Cooperative Oncology Group
- Deep
We haven't built an HCP commentary report on EAA241 (daratumumab-hyaluronidase, cyclophosphamide and 2 more in Myeloma Multiple) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EAA241 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 50 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Trial Comparing Daratumumab-Bortezomib-Dexamethasone Versus Cyclophosphamide-Bortezomib-Dexamethasone in Newly Diagnosed Multiple Myeloma With Light Chain Cast Nephropathy (LCCN)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Myeloma Multiple
- Interventions
- Cyclophosphamide; Bortezomib (VELCADE); Dexamethasone; Daratumumab-hyaluronidase
- Arms
- ARM A (Cy-Bor-Dex) · Active comparator
- ARM B (Dara-Bor-Dex) · Experimental
- Enrollment
- 74 (estimated)
- Primary outcomes
- Renal Response Rate
- Sponsor
- Eastern Cooperative Oncology Group with National Cancer Institute (NCI)
- Start
- Mar 5, 2026
- Primary completion
- Jan 11, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07085728 · updated Sep 14, 2026